Dexcom rebounds from COVID-19 dip as demand returns for wearable glucose monitors
Excerpt from the Article:
“In April, San Diego’s Dexcom saw a slowdown in patients signing up for its continuous glucose monitors as consumers hunkered down and doctors transitioned to tele-medicine because of the COVID-19 pandemic.
The question was how long would the dip last?
As it turned out, not very long. As physicians and patients got comfortable with remote visits, demand for glucose monitors returned in May and June, ushering in a strong second quarter for Dexcom.
The company announced this week that revenue surged 34 percent year over year to $452 million. Adjusted earnings came in at $77 million, or 79 cents per share.”
Click the button below to read the Article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?